AAN Issues Findings on Use of Medical Marijuana in Treatment of Certain Brain Diseases
Not enough evidence was found to show if medical marijuana is helpful in treating motor problems in Huntington’s disease, tics in Tourette syndrome, cervical dystonia and seizures in epilepsy. The review is published in the April 29, 2014, print issue of Neurology®, the medical journal of the American Academy of Neurology (AAN), and will be presented at the AAN Annual Meeting in Philadelphia, April 26-May 3, 2014, which is the world’s largest gathering of neurologists.
“This review by the world’s largest association for neurologists is intended to help neurologists and their patients understand the current research on medical marijuana for the treatment of certain brain diseases,” said review author Barbara S. Koppel, MD, of New York Medical College in New York and Fellow of the American Academy of Neurology. “The AAN review also highlights the need for more high-quality studies of the long-term efficacy and safety of medical marijuana in the treatment of neurologic diseases.”
The AAN review concluded that certain forms of medical marijuana (only in pill or oral spray form) can help treat some symptoms of MS. These include spasticity, certain types of pain (pain related to spasticity, including painful spasms, and painful burning and numbness), and overactive bladder.
Most of the MS studies examined pill or oral spray forms of medical marijuana. There were two studies that examined smoked medical marijuana for treating MS symptoms. However, the studies did not provide enough information to show if smoked medical marijuana is effective. “It’s important to note that medical marijuana can worsen thinking and memory problems, and this is a concern since many people with MS suffer from these problems already due to the disease itself,” said Koppel.
For Parkinson’s disease, the AAN review concluded that medical marijuana in the form of synthetic tetrahydrocannabinol (THC) pills likely does not help relieve abnormal movements that can develop in the late stages of the disease from the drug levodopa, which is the main drug used to treat shaking, stiffness and slowness of movements.
The AAN review also concluded that there is not enough information to show if medical marijuana, including smoked medical marijuana, is safe or effective in these neurologic diseases:
- Motor symptoms in Huntington’s disease
- Tics in Tourette syndrome
- Cervical dystonia (abnormal neck movements)
- Seizures in epilepsy
There are safety concerns with medical marijuana use. Side effects reported in at least two studies were nausea, increased weakness, behavioral or mood changes, suicidal thoughts or hallucinations, dizziness or fainting symptoms, fatigue, and feelings of intoxication. There was one report of a seizure.
Mood changes and suicidal thoughts are of special concern for people with MS, who are at an increased risk for depression or suicide. The studies showed the risk of serious psychological effects is about 1 percent, or one in every 100 people.
In general, medical marijuana is prescribed as a treatment for use only when standard treatment has not helped.
The review is endorsed by the American Autonomic Society, the American Epilepsy Society and the International Rett Syndrome Foundation.
To learn more about brain health, please visit www.aan.com/patients.
The American Academy of Neurology, an association of more than 27,000 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer’s disease, stroke, migraine, multiple sclerosis, brain injury, Parkinson’s disease and epilepsy.
For more information about the American Academy of Neurology, visit http://www.aan.comor find us onFacebook, Twitter, Google+ and YouTube.
Editor’s Note:
Dr. Koppel will present her findings at a press conference at 10:00 a.m. ET, on Monday, April 28, 2014, in the AAN Press Conference Room, 103C of the Pennsylvania Convention Center in Philadelphia. To obtain press conference call-in information, please contact Rachel Seroka, rseroka@aan.com.
Dr. Koppel is available for advance interviews as well. Please contact Rachel Seroka, rseroka@aan.com, to schedule an advance interview.
Rachel L. Seroka Manager, Media and Public Relations American Academy of Neurology 201 Chicago Avenue Minneapolis, MN 55415 Ph: 612-928-6129 Mobile: 612-807-6968 Fax: 612-454-2744 rseroka@aan.comMedia Contact
All latest news from the category: Studies and Analyses
innovations-report maintains a wealth of in-depth studies and analyses from a variety of subject areas including business and finance, medicine and pharmacology, ecology and the environment, energy, communications and media, transportation, work, family and leisure.
Newest articles
Compact LCOS Microdisplay with Fast CMOS Backplane
…for High-Speed Light Modulation. Researchers from the Fraunhofer Institute for Photonic Microsystems IPMS, in collaboration with HOLOEYE Photonics AG, have developed a compact LCOS microdisplay with high refresh rates that…
New perspectives for material detection
CRC MARIE enters third funding period: A major success for terahertz research: Scientists at the University of Duisburg-Essen and the Ruhr University Bochum have been researching mobile material detection since…
CD Laboratory at TU Graz Researches New Semiconductor Materials
Using energy- and resource-saving methods, a research team at the Institute of Inorganic Chemistry at TU Graz aims to produce high-quality doped silicon layers for the electronics and solar industries….